Bangladesh has moved to bolster its pharmaceutical sector through a series of new partnerships between its national research body and leading drug manufacturers, in a step aimed at enhancing global competitiveness and accelerating innovation.
The Bangladesh Council of Scientific and Industrial Research (BCSIR) has signed multiple service agreements with top domestic pharmaceutical companies and the international research organisation icddr,b.
The agreements are designed to improve analytical services, quality control, testing, method development and clinical research capabilities across the industry, aligning Bangladesh’s pharmaceutical output more closely with international standards.
Among the companies signing separate deals with BCSIR are Incepta Pharmaceuticals Limited, Beximco Pharmaceuticals PLC and Square Pharmaceuticals Limited, alongside several other major firms in the sector.
Officials say the initiative will allow participating companies priority access to BCSIR’s advanced laboratories, high-end scientific equipment and technical expertise. This is expected to significantly reduce testing turnaround times and improve reliability in areas such as raw material verification, finished product quality and regulatory documentation.
A separate clinical research agreement with icddr,b will expand cooperation in areas including bioequivalence studies, joint research initiatives and data sharing. A non-disclosure agreement has also been signed to support secure collaboration and knowledge exchange.
Speaking at the signing ceremony, Science and Technology Secretary Md Anwar Hossain highlighted the importance of closer ties between research institutions and industry. He said such partnerships are essential to building a technology-driven industrial base and enabling faster access to scientific services.
BCSIR Chair Dr Samina Ahmed reiterated the government’s commitment to strengthening industry–research collaboration, describing the agreements as a strategic step towards expanding Bangladesh’s pharmaceutical capabilities.
Bangladesh’s pharmaceutical sector has seen steady growth in recent years and is increasingly competing in international markets. Industry observers believe these agreements could play a key role in scaling up capacity, improving compliance with global standards and supporting innovation-led growth.
The move also reflects a broader ambition to translate laboratory research into industrial application — often described as a “lab to industry” approach — as Bangladesh seeks to position itself as a knowledge-based, technology-driven economy.